| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2013-02-26 |
| タイトル |
|
|
タイトル |
Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Oxicam |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Non-steroidal anti-inflammatory drug |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Neuroprotection |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Parkinson’s disease |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Akt |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
1-methyl-4-phenyl pyridinium |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| 著者 |
田崎, 嘉一
Yamamoto, Joe
Omura, Tomohiro
Noda, Toshihiro
Kamiyama, Naoya
Yoshida, Koichi
Satomi, Machiko
Sakaguchi, Tomoki
Asari, Masaru
Ohkubo, Tomoko
Shimizu, Keiko
Matsubara, Kazuo
|
| 書誌情報 |
European journal of pharmacology
巻 676,
号 1-3,
p. 57-63,
発行日 2012-02-01
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0014-2999 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.ejphar.2011.11.046 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
In the treatment of Parkinson's disease, potent disease-modifying drugs are still needed to halt progressive dopaminergic neurodegeneration. We have previously shown that meloxicam, an oxicam non-steroidal anti-inflammatory drug (NSAID), elicits a potent neuroprotective effect against 1-methyl-4-phenyl pyridinium (MPP(+))-induced toxicity in human dopaminergic SH-SY5Y neuroblastoma cells. This cyclooxygenase-independent neuroprotection of meloxicam is mediated via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway; however, the specific chemical structure involved in inducing neuroprotection remains unresolved. In this study, we therefore investigated the structure-specific for eliciting the neuroprotective effect by examining a series of NSAIDs against MPP(+) toxicity in SH-SY5Y cells. Three oxicam-bearing NSAIDs showed potent neuroprotective effects, although none of the other 10 oxicam-nonbearing NSAIDs (3 salicylates, 6 coxibs and 1 polyphenol) or 3 piroxicam analogs (including ampiroxicam, a precursor of piroxicam) exerted any neuroprotection. Tenoxicam and piroxicam prevented MPP(+)-induced reduction of phosphorylated Akt levels in cells: a protective mechanism similar to that of meloxicam. Therefore, the oxicam structure was likely to be responsible for exhibiting the neuroprotection by sustaining survival-signaling in dopaminergic cells. The present results raise the possibility that the oxicam-bearing NSAIDs may serve as potential therapeutic drugs to retard or terminate progression of Parkinson's disease via a novel mechanism. |
|
言語 |
en |
| 注記 |
|
|
内容記述タイプ |
Other |
|
注記 |
Author |
| 資源タイプ |
|
|
内容記述タイプ |
Other |
|
資源タイプ |
text |
| 著者版フラグ |
|
|
出版タイプ |
AM |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
| ID(XooNIps) |
|
|
|
22182582 |
| 閲覧数(XooNIps) |
|
| ダウンロード数(XooNIps) |
|
|
|
1028 |
5064.pdf (1.3 MB)
